Background: There is an urgent need to improve lung cancer outcome by identifying and
INTRODUCTION
Over 80% of lung cancers are attributed to tobacco exposure; however, fewer than 20% of smokers will develop lung cancer in their lifetime (1) (2) (3) . This is a classic example of genetic host susceptibility as a modulator of an exposed individual's risk for development of cancer (4) .
Genetically determined modulation of environmental exposures is an attractive mechanism to explain the variation of individual susceptibility among current and former smokers (5) . Since biologic variability may occur at any stage of carcinogenesis, the variation in inter-individual susceptibility poses a challenge in quantitative human risk assessment and warrants testing and validation of biomarkers that allow accurate identification of high risk individuals.
A crucial early event in carcinogenesis is the induction of the genomic instability phenotype, which enables an initiated cell to evolve into a cancer cell by achieving a greater proliferative capacity (6) . Such instability is mediated through chromosomal changes, at a gross level, and is therefore cytogenetically detected (7) . Evidence that cytogenetic biomarkers are positively correlated with cancer risk has been strongly validated in both cohort and nested case-control studies, leading to the conclusion that chromosome aberrations are a relevant marker of cancer risk (8) (9) (10) (11) (12) , reflecting the outcome of both the genotoxic effects of carcinogens and the genetic host susceptibility.
The cytokinesis-blocked micronucleus assay (CBMN) is a commonly used method for measuring DNA damage (13) . This multi-endpoint assay simultaneously assesses DNA damage endpoints in the form of micronuclei, nucleoplasmic bridges and nuclear buds as well as other cellular events such as necrosis, apoptosis and cell proliferation (14) . Micronuclei in binucleated cells (BN-MN) are identified as chromosome fragments or whole chromosomes that fail to engage with the mitotic spindle; nucleoplasmic bridges in binucleated cells (BN-NPBs) originate from asymmetrical chromosome rearrangements and/or telomere end-fusions (15, 16) and nuclear buds in binucleated cells (BN-NBUDs) represent a mechanism by which cells remove amplified DNA and are markers of possible gene amplification (17) .
We have previously reported in a pilot study and confirmed in a larger study (18) (19) (20) that BN-MN and BN-NPB are strong predictors of lung cancer susceptibility with an overall positive predictive value of 96.1 and negative predictive value of 89.7 associated with disease status (19) .
In the current study, we externally validate our findings in an independent lung cancer population and test the effect of extending an existing lung cancer risk prediction model (21) with the CBMN endpoints. To date, several lung cancer prediction risk models have been developed [Bach, Spitz, 
Liverpool Lung Project, Prostate Lung Colon Ovary and European
Prospective Investigation into Cancer and Nutrition] based on epidemiological risk factors with a wide range of discriminatory power (21) (22) (23) (24) (25) . Only two of such models have been extended by the addition of biomarkers; however, the resulting improvement in discriminatory power is only modest (26) (27) (28) . Our data show that the extension of the Spitz model with the BN-MN endpoint leads to a substantial improvement in the discriminatory power of the model among all smoking strata.
MATERIALS and METHODS

Study Participants
A total of 1,506 participants comprised the study test set of 995 study participants (527 cases / 468 controls) and validation set of 511 study participants (239 cases / 272 controls). A complete epidemiologic questionnaire was administered and CBMN assay was conducted. The study was approved by institutional review boards at the University of Texas MD Anderson Cancer Center (MDACC), Kelsey-Seybold Clinics, Massachusetts General Hospital (MGH), and the Harvard School of Public Health. All subjects provided written informed consent for participation.
Lung cancer cases
Lung cancer patients were recruited at both MDACC in Houston and MGH in Boston. (±5 years), sex, ethnicity, and smoking status (never, former, or current) and used for the model development and internal validation part of the study. An independent set of 272 healthy controls, that were mutually exclusive from the internal validation set, were frequency-matched to the MGH lung cancer cases on age (± 5 years), gender and smoking status and used to create a comparison group for the MGH lung cancer cases in the external validation part of the study.
For all participants, former smokers were individuals who had smoked at least 100 cigarettes in their lifetime but quit at least 12 months prior to lung cancer diagnosis (for cases) or prior to the interview (for controls). Current smokers include those currently smoking and "recent quitters"
[i.e., those who quit within the last 12 months from diagnosis (for cases) or interview (for controls)]. Data on smoking history include smoking duration, number of cigarettes smoked per day, computed pack-years smoked, and age at smoking initiation for all smokers plus age at smoking cessation and computed years since cessation for former smokers. Smoking duration was determined by subtracting the age at which the participant had started smoking from either the age at which the participant had quit smoking (former smokers) or the participant's current age (current smokers). Pack-years were calculated by multiplying the smoking duration (in years) by the number of cigarettes smoked per day and then dividing by 20. Time of smoking cessation for former smokers was determined by subtracting the age at which the participant had quit smoking from the participant's current age. Participants were classified as positive for asbestos or wood dusts (sanding or sawdust) exposures if they had been directly exposed for at least 8 hours/week for a year. Participants were classified as positive for a family history of any cancer if at least two first-degree relatives had cancer and positive for a family history of any smoking-related cancer if at least one first-degree relative had a smoking-related cancer. fever at any time prior to study entry. The MGH cases did not provide hay fever information; therefore we did not include this variable in our extended model.
Lymphocyte Cultures for CBMN Assay
The CBMN assay was performed following the standard cytokinesis-block technique (29, 30) and duplicate lymphocyte cultures were prepared for each study subject (20) (21) (22) . Slides were scored blindly following the well-established HUMN Project criteria (29) (30) (31) . Briefly, a cell was identified as binulceated if it contained two nuclei with intact nuclear membranes, an intact cytoplasmic boundary and an intact cell membrane. An event was recorded as a MN if the morphology was identical to that of the two nuclei but smaller, non-retractile and not connected to the main nucleus. An event was recorded as a nucleoplasmic bridge if the connection between the two nuclei was non-retractile and had the same staining quality as the main nuclei. For each sample, 1000 binucleated cells were evaluated and BN-MN and BN-NPB endpoints were recorded. The assay was conducted blinded to case-control status and run consecutively as cases and controls were enrolled into the study, which should nullify selection bias in assay data availability. All MDACC samples were assayed and scored at MDACC. The MGH samples were assayed at Harvard and the blinded slides were sent to MDACC for scoring.
Statistical Methods
External Validation of the CBMN assay
Statistical analyses were performed using SAS and STATA software. 
Development of Extended Spitz Model
Data from MDACC lung cancer cases and controls were used to develop the CBMN extended models for never, former and current smokers, separately. We retained the original epidemiologic variables of the Spitz model (21) 
Validation of the Extended Spitz Model
The MGH lung cancer cases and independent controls were used to validate the extended Spitz model and to evaluate the increase in discriminatory power. For each model, we calculated the area under the receiver operator characteristic curve (AUC). Within each smoking group, we performed pairwise comparisons of the AUCs to evaluate model improvement upon marker addition. To further evaluate improvement in discriminatory power within each smoking stratum, we calculated the increase in improvement in risk prediction using the net reclassification improvement method (32) . In addition, we compared the positive predictive value and negative Table 1 summarizes the demographics and matching variables for MDACC and MGH study subjects. Mean age +SD of MDACC study population was 62 + 10.8 (cases) and 59 + 12.1 (controls) (p<0.001). On average, controls were 3 years younger but within the 5-year age matching criterion. Cases were significantly heavier smokers than controls measured by pack years. Self-reported histories of COPD, dust and asbestos exposure were significantly higher among cases. Demographic details for the MGH external validation study subjects and the independent MDACC controls are also summarized in Table 1 . Cases (n=239) and controls (n=272) were well matched on age, gender and smoking status. Mean age +SD was 65 + 10.7 for cases and 64 + 11.0 for controls. History of COPD but not dust or asbestos exposure was significantly higher among the cases.
RESULTS
Subject's Characteristics
Distribution of CBMN-endpoints MDACC population
Mean CBMN biomarker endpoints, BN-MN and BN-NPB were significantly higher in the cases (Table 2) 
MGH population
Similar to the MDACC population, the mean CBMN biomarker endpoints, BN-MN and BN-NPB were significantly higher in cases ( Table 4 
Multivariable Risk Model [The Extended Spitz Model]
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Predictive Capability of the Extended Model
DISCUSSION
In a proof of principle study we reported and confirmed (18) (19) (20) that the CBMN assay is a strong predictor of lung cancer risk. Here, we validate the use of the assay as a sensitive marker for lung cancer risk in an independent lung cancer population recruited from a similar study in a different state. The levels of BN-MN observed were similar between the 2 populations, overall and after stratification by age, gender and smoking status. The significantly higher genetic damage observed in cases confirms the role of genetic instability in the carcinogenic process. Our controls were recruited from one state; however, since the measurements between the two case populations were almost identical, there is no reason to expect differences among the control population.
Our group developed the Spitz risk model (21) as the mutagen sensitivity, that only measures the DNA damaging effect of a mutagen in the G 2 phase and reflects the sensitivity of the cells to exposure to chemicals without consideration of other parameters such as repair. Furthermore, micronuclei are now recognized as mechanisms by which the recently discovered phenomena chromothripsis and chromoanagenesis, may occur.
These phenomena are now being recognized as potential major contributors to the initiation and development of human cancer (39, 40) . Chromothripsis involves chromosome shattering of one or a few chromosomes leading to a large number of rearrangements while chromoanageneis describes complex genomic rearrangements that occur as a single catastrophic event rather than a series of independent arrangements (41). Both mechanisms involve massive damage to a very small subset of chromosomes or chromosome arms that were found to be confined within micronuclei (40) .
Prevention of even 10% of annual deaths from lung cancer would save an estimated 17,000 lives, equivalent to all the annual deaths in the United States from ovarian cancer and almost all the annual deaths from brain cancers. Recent findings from the national lung screening trial showed a 20% reduction in lung cancer mortality among participants screened with CT compared to chest x-rays. However, national lung screening trial results also indicate that to prevent one death from lung cancer, 320 high-risk individuals must be screened (42). The definition of high risk individuals based solely on age and pack years has resulted in unnecessary additional clinical testing and overtreatment. In order to identify the "true high risk" individuals, it is imperative to consider validated biomarkers of risk. Our study showed that the CBMN assay is an exquisitely sensitive and specific predictor of lung cancer risk and that the extension of the Spitz model led to an AUC that may prove useful in population screening programs. Clinically, the ability to 
identify high-risk subgroups that might benefit from increased screening surveillance that is not appropriate for low-risk individuals, has immense public health significance. Resulting p-values from comparing endpoints between cases and controls (BN-MN or BN-NPB) overall or stratified by age, gender or smoking status. Mean differences between MDACC cases and controls were significant at the 0.0001 level within all stratum. Mean differences between MGH cases and control were significant at the 0.0001 level within all stratum. Mean BN-MN differences between MDACC cases and MGH cases were not significant (P>0.05) within all stratum. Mean BN-NPB differences between MDACC cases and MGH cases were significant (P<0.05) within all stratum. 
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